Loading...

Adriana Tremoulet

TitleTeacher
InstitutionUniversity of California San Diego
Address9500 Gilman Drive #0641
La Jolla CA 92093
Phone858-246-0012
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Diego, San Diego, CAMAS06/2009Master in Clinical Research
    University of California, San Diego, San Diego, CA06/2006Peds ID Fellowship
    Cedars Sinai Medical Center, Los Angeles, CA06/2003Pediatric Residency
    University of California, Los Angeles, Los Angeles, CAMD06/2000Medicine
    Harvard University, Boston, MAAB06/1995Biochemistry

    Collapse Overview 
    Collapse Overview
    Dr. Adriana (Adri) Tremoulet is an Associate Professor of Clinical Pediatrics in the Division of Host-Microbe Systems and Therapeutics in the Department of Pediatrics at UC San Diego, specializing in pediatric infectious diseases and clinical pharmacology. She serves as the Associate Director of the Kawasaki Disease (KD) Research Center at UC San Diego, caring for nearly 1700 children with KD in San Diego County and an additional 100 children annually hospitalized at Rady Children’s Hospital San Diego with KD. The primary focus of her research is repurposing therapeutics in Phase I through III clinical trials for inflammatory and infectious disorders. She has a passion for pediatric pharmacology and serves as the co-principal investigator of the NIH-funded UC San Diego Research Program in Developmental Pharmacology (RPDP) as well as co-Director of the UC San Diego Department of Pediatric Clinical Pharmacology Training Program and Altman Clinical Trials Research Institute KL2 progam. She also serves as the UC San Diego site PI for the NICHD funded Pediatric Trials Network. She is currently leading Phase I/IIa clinical trials of atorvastatin and anakinra in children with KD and coronary artery damage. As a native Spanish speaker, she has established the KD Latin American Network that collaborates in 20 Latin American countries in the collection of clinical and phenotypic data of KD patients to better understand the impact of KD in this region of the world.


    Collapse Research 
    Collapse Research Activities and Funding
    Innate Immune Activation and Endothelial Cell Dysfunction in Acute Kawasaki Disease
    NIH/NHLBI R01HL140898Jan 1, 2018 - Nov 30, 2022
    Role: Co-Principal Investigator
    Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases
    NIH/NICHD U54HD090259Sep 20, 2016 - Jun 30, 2021
    Role: Principal Investigator
    Developing Pediatric Clinical Pharmacologists for the Advancement of Therapeutics
    NIH/NICHD T32HD087978May 1, 2016 - Apr 30, 2021
    Role: Principal Investigator
    Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease
    NIH/NICHD R01HD081296Sep 23, 2014 - Jun 30, 2018
    Role: Principal Investigator
    Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
    NIH/NICHD K23HD056939Sep 1, 2007 - Aug 31, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News
    Collapse Featured Presentations
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wright VJ, Herberg JA, Kaforou M, Shimizu C, Eleftherohorinou H, Shailes H, Barendregt AM, Menikou S, Gormley S, Berk M, Hoang LT, Tremoulet A, Kanegaye JT, Coin LJM, Glodé MP, Hibberd M, Kuijpers TW, Hoggart CJ, Burns JC, Levin M. Diagnosis of Kawasaki Disease Using a Minimal Whole-Blood Gene Expression Signature. JAMA Pediatr. 2018 Aug 06; e182293. PMID: 30083721.
      View in: PubMed
    2. Jaggi P, Mejias A, Xu Z, Yin H, Moore-Clingenpeel M, Smith B, Burns JC, Tremoulet A, Jordan-Villegas A, Chaussabel D, Texter K, Pascual V, Ramilo O. Whole blood transcriptional profiles as a prognostic tool in complete and incomplete Kawasaki Disease. PLoS One. 2018; 13(5):e0197858. PMID: 29813106.
      View in: PubMed
    3. Vande Casteele N, Oyamada J, Shimizu C, Best BM, Capparelli EV, Tremoulet A, Burns JC. Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. Clin Pharmacokinet. 2018 Apr 05. PMID: 29623653.
      View in: PubMed
    4. Franco A, Kumar J, Lin G, Behnamfar N, Hsieh LE, Shimizu C, Tremoulet A, Burns JC, Linden J. Pediatric tolerogenic DCs expressing CD4 and immunoglobulin-like transcript receptor (ILT)-4 secrete IL-10 in response to Fc and adenosine. Eur J Immunol. 2018 Mar; 48(3):482-491. PMID: 29244203.
      View in: PubMed
    5. Kim GJ, Capparelli E, Romanowski G, Proudfoot JA, Tremoulet A. Development of Tolerance to Chronic Intermittent Furosemide Therapy in Pediatric Patients. J Pediatr Pharmacol Ther. 2017 Nov-Dec; 22(6):394-398. PMID: 29290738.
      View in: PubMed
    6. Tremoulet A. Adjunctive therapies in Kawasaki disease. Int J Rheum Dis. 2018 Jan; 21(1):76-79. PMID: 29076637.
      View in: PubMed
    7. Lee B, Kofman CD, Tremoulet A, Kuo DJ. Fever without a source: evolution of a diagnosis from Kawasaki disease to acute myelogenous leukaemia. BMJ Case Rep. 2017 May 06; 2017. PMID: 28478386.
      View in: PubMed
    8. Salgado AP, Ashouri N, Berry EK, Sun X, Jain S, Burns JC, Tremoulet A. High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease. J Pediatr. 2017 Jun; 185:112-116.e1. PMID: 28408126.
      View in: PubMed
    9. Lee AM, Burns JC, Tremoulet A. Safety of Infliximab Following Live Virus Vaccination in Kawasaki Disease Patients. Pediatr Infect Dis J. 2017 Apr; 36(4):435-437. PMID: 27918378.
      View in: PubMed
    10. Kim J, Shimizu C, Kingsmore SF, Veeraraghavan N, Levy E, Ribeiro Dos Santos AM, Yang H, Flatley J, Hoang LT, Hibberd ML, Tremoulet A, Harismendy O, Ohno-Machado L, Burns JC. Whole genome sequencing of an African American family highlights toll like receptor 6 variants in Kawasaki disease susceptibility. PLoS One. 2017; 12(2):e0170977. PMID: 28151979.
      View in: PubMed
    11. Burns JC, Koné-Paut I, Kuijpers T, Shimizu C, Tremoulet A, Arditi M. Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease. Arthritis Rheumatol. 2017 Feb; 69(2):268-276. PMID: 27792871.
      View in: PubMed
    12. Wang Y, Li Z, Hu G, Hao S, Deng X, Huang M, Ren M, Jiang X, Kanegaye JT, Ha KS, Lee J, Li X, Jiang X, Yu Y, Tremoulet A, Burns JC, Whitin JC, Shin AY, Sylvester KG, McElhinney DB, Cohen HJ, Ling XB. Unique Molecular Patterns Uncovered in Kawasaki Disease Patients with Elevated Serum Gamma Glutamyl Transferase Levels: Implications for Intravenous Immunoglobulin Responsiveness. PLoS One. 2016; 11(12):e0167434. PMID: 28002448.
      View in: PubMed
    13. He M, Chen Z, Martin M, Zhang J, Sangwung P, Woo B, Tremoulet A, Shimizu C, Jain MK, Burns JC, Shyy JY. miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease. Circ Res. 2017 Jan 20; 120(2):354-365. PMID: 27923814.
      View in: PubMed
    14. Shimizu C, Eleftherohorinou H, Wright VJ, Kim J, Alphonse MP, Perry JC, Cimaz R, Burgner D, Dahdah N, Hoang LT, Khor CC, Salgado A, Tremoulet A, Davila S, Kuijpers TW, Hibberd ML, Johnson TA, Takahashi A, Tsunoda T, Kubo M, Tanaka T, Onouchi Y, Yeung RS, Coin LJ, Levin M, Burns JC. Genetic Variation in the SLC8A1 Calcium Signaling Pathway Is Associated With Susceptibility to Kawasaki Disease and Coronary Artery Abnormalities. Circ Cardiovasc Genet. 2016 Dec; 9(6):559-568. PMID: 27879314.
      View in: PubMed
    15. Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet A, Mahavadi VS, Baker A, deFerranti SD, Fulton DR, Burns JC, Newburger JW. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population. J Am Heart Assoc. 2016 Sep 15; 5(9). PMID: 27633390.
      View in: PubMed
    16. Connelly MA, Shimizu C, Winegar DA, Shalaurova I, Pourfarzib R, Otvos JD, Kanegaye JT, Tremoulet A, Burns JC. Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children. BMC Pediatr. 2016 09 05; 16(1):151. PMID: 27596163; PMCID: PMC5011873.
    17. Hornik CP, Benjamin DK, Smith PB, Pencina MJ, Tremoulet A, Capparelli EV, Ericson JE, Clark RH, Cohen-Wolkowiez M. Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates. J Pediatr. 2016 Nov; 178:125-129.e1. PMID: 27522443.
      View in: PubMed
    18. Herberg JA, Kaforou M, Wright VJ, Shailes H, Eleftherohorinou H, Hoggart CJ, Cebey-López M, Carter MJ, Janes VA, Gormley S, Shimizu C, Tremoulet A, Barendregt AM, Salas A, Kanegaye J, Pollard AJ, Faust SN, Patel S, Kuijpers T, Martinón-Torres F, Burns JC, Coin LJ, Levin M. Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children. JAMA. 2016 Aug 23-30; 316(8):835-45. PMID: 27552617.
      View in: PubMed
    19. Hao S, Jin B, Tan Z, Li Z, Ji J, Hu G, Wang Y, Deng X, Kanegaye JT, Tremoulet A, Burns JC, Cohen HJ, Ling XB. A Classification Tool for Differentiation of Kawasaki Disease from Other Febrile Illnesses. J Pediatr. 2016 Sep; 176:114-120.e8. PMID: 27344221; PMCID: PMC5003696 [Available on 09/01/17].
    20. Doan S, Maehara CK, Chaparro JD, Lu S, Liu R, Graham A, Berry E, Hsu CN, Kanegaye JT, Lloyd DD, Ohno-Machado L, Burns JC, Tremoulet A. Building a Natural Language Processing Tool to Identify Patients With High Clinical Suspicion for Kawasaki Disease from Emergency Department Notes. Acad Emerg Med. 2016 05; 23(5):628-36. PMID: 26826020.
      View in: PubMed
    21. Tremoulet A, Jain S, Kim S, Newburger J, Arditi M, Franco A, Best B, Burns JC. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). Contemp Clin Trials. 2016 05; 48:70-5. PMID: 27080929.
      View in: PubMed
    22. Haddock ES, Calame A, Shimizu C, Tremoulet A, Burns JC, Tom WL. Psoriasiform eruptions during Kawasaki disease (KD): A distinct phenotype. J Am Acad Dermatol. 2016 Jul; 75(1):69-76.e2. PMID: 26946987; PMCID: PMC4912865 [Available on 07/01/17].
    23. Li Z, Tan Z, Hao S, Jin B, Deng X, Hu G, Liu X, Zhang J, Jin H, Huang M, Kanegaye JT, Tremoulet A, Burns JC, Wu J, Cohen HJ, Ling XB. Urinary Colorimetric Sensor Array and Algorithm to Distinguish Kawasaki Disease from Other Febrile Illnesses. PLoS One. 2016; 11(2):e0146733. PMID: 26859297; PMCID: PMC4747548.
    24. Kanegaye JT, Jones JM, Burns JC, Jain S, Sun X, Jimenez-Fernandez S, Berry E, Pancheri JM, Jaggi P, Ramilo O, Tremoulet A. Axillary, Oral and Rectal Routes of Temperature Measurement During Treatment of Acute Kawasaki Disease. Pediatr Infect Dis J. 2016 Jan; 35(1):50-3. PMID: 26398742; PMCID: PMC4706471 [Available on 01/01/17].
    25. Numano F, Shimizu C, Tremoulet A, Dyar D, Burns JC, Printz BF. Pulmonary Artery Dilation and Right Ventricular Function in Acute Kawasaki Disease. Pediatr Cardiol. 2016 Mar; 37(3):482-90. PMID: 26681305.
      View in: PubMed
    26. Jaggi P, Wang W, Dvorchik I, Printz B, Berry E, Kovalchin JP, Texter K, Ramilo O, Burns JC, Tremoulet A. Patterns of Fever in Children After Primary Treatment for Kawasaki Disease. Pediatr Infect Dis J. 2015 Dec; 34(12):1315-8. PMID: 26353031; PMCID: PMC4718845 [Available on 12/01/16].
    27. Tremoulet A, Dutkowski J, Sato Y, Kanegaye JT, Ling XB, Burns JC. Novel data-mining approach identifies biomarkers for diagnosis of Kawasaki disease. Pediatr Res. 2015 Nov; 78(5):547-53. PMID: 26237629; PMCID: PMC4628575.
    28. Numano F, Shimizu C, Jimenez-Fernandez S, Vejar M, Oharaseki T, Takahashi K, Salgado A, Tremoulet A, Gordon JB, Burns JC, Daniels LB. Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms. Int J Cardiol. 2015 Dec 15; 201:429-37. PMID: 26313861.
      View in: PubMed
    29. Tremoulet A, Jain S, Burns JC. Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: A Phase I/IIa trial of atorvastatin. Expert Opin Orphan Drugs. 2015; 3(9):967-970. PMID: 27525197.
      View in: PubMed
    30. Burns JC, Touma R, Song Y, Padilla RL, Tremoulet A, Sidney J, Sette A, Franco A. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease. Autoimmunity. 2015 May; 48(3):181-8. PMID: 25822882; PMCID: PMC4784966.
    31. Tremoulet A. The role of statins in inflammatory vasculitides. Autoimmunity. 2015 May; 48(3):177-80. PMID: 25822883.
      View in: PubMed
    32. Hoang LT, Shimizu C, Ling L, Naim AN, Khor CC, Tremoulet A, Wright V, Levin M, Hibberd ML, Burns JC. Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease. Genome Med. 2014; 6(11):541. PMID: 25614765; PMCID: PMC4279699.
    33. Ulloa-Gutierrez R, Salgado AP, Tremoulet A. Kawasaki Disease in Latin American Children: Past, Current, and Future Challenges. J Pediatric Infect Dis Soc. 2014 Dec; 3(4):280-1. PMID: 26625447.
      View in: PubMed
    34. Chao T, Perry JC, Romanowski GL, Tremoulet A, Capparelli EV. Optimizing pediatric esmolol dosing using computerized practitioner order entry. J Pediatr Pharmacol Ther. 2014 Oct-Dec; 19(4):302-9. PMID: 25762876; PMCID: PMC4341416.
    35. Lin J, Jain S, Sun X, Liu V, Sato YZ, Jimenez-Fernandez S, Newfield RS, Pourfarzib R, Tremoulet A, Gordon JB, Daniels LB, Burns JC. Lipoprotein particle concentrations in children and adults following Kawasaki disease. J Pediatr. 2014 Oct; 165(4):727-31. PMID: 25039043; PMCID: PMC4207833.
    36. González-Mata A, Ulloa-Gutiérrez R, Brea J, Soza G, Tremoulet A. Origin and importance of the Latin American Kawasaki Disease Network (REKAMLATINA). Rev Chilena Infectol. 2014 Jun; 31(3):330-2. PMID: 25146208.
      View in: PubMed
    37. Tremoulet A, Le J, Poindexter B, Sullivan JE, Laughon M, Delmore P, Salgado A, Ian-U Chong S, Melloni C, Gao J, Benjamin DK, Capparelli EV, Cohen-Wolkowiez M. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. Antimicrob Agents Chemother. 2014 Jun; 58(6):3013-20. PMID: 24614374.
      View in: PubMed
    38. Tremoulet A, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014 May 17; 383(9930):1731-8. PMID: 24572997.
      View in: PubMed
    39. Franco A, Touma R, Song Y, Shimizu C, Tremoulet A, Kanegaye JT, Burns JC. Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity. 2014 Mar; 47(2):95-104. PMID: 24490882.
      View in: PubMed
    40. Ogata S, Shimizu C, Franco A, Touma R, Kanegaye JT, Choudhury BP, Naidu NN, Kanda Y, Hoang LT, Hibberd ML, Tremoulet A, Varki A, Burns JC. Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G. PLoS One. 2013; 8(12):e81448. PMID: 24324693; PMCID: PMC3855660.
    41. Burns JC, Song Y, Bujold M, Shimizu C, Kanegaye JT, Tremoulet A, Franco A. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clin Exp Immunol. 2013 Dec; 174(3):337-44. PMID: 23901839; PMCID: PMC3826300.
    42. Leuin SC, Shanbhag S, Lago D, Sato Y, Sun X, Jain S, Burns JC, Tremoulet A. Hoarseness as a presenting sign in children with Kawasaki disease. Pediatr Infect Dis J. 2013 Dec; 32(12):1392-4. PMID: 23811742; PMCID: PMC3887132.
    43. Tremoulet A. Comment on atorvastatin safety in kawasaki disease patients with coronary artery aneurysms. Pediatr Cardiol. 2014 Jan; 35(1):93. PMID: 24072043.
      View in: PubMed
    44. Burns JC, Herzog L, Fabri O, Tremoulet A, Rodó X, Uehara R, Burgner D, Bainto E, Pierce D, Tyree M, Cayan D. Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013; 8(9):e74529. PMID: 24058585; PMCID: PMC3776809.
    45. González-Mata A, Ulloa-Gutierrez R, Brea del Castillo J, Soza G, Tremoulet A. [Origin and importance of the Latin American Kawasaki Disease Network (REKAMLATINA)]. Rev Chilena Infectol. 2013 Aug; 30(4):402-4. PMID: 24248109.
      View in: PubMed
    46. Ogata S, Tremoulet A, Sato Y, Ueda K, Shimizu C, Sun X, Jain S, Silverstein L, Baker AL, Tanaka N, Ogihara Y, Ikehara S, Takatsuki S, Sakamoto N, Kobayashi T, Fuse S, Matsubara T, Ishii M, Saji T, Newburger JW, Burns JC. Coronary artery outcomes among children with Kawasaki disease in the United States and Japan. Int J Cardiol. 2013 Oct 09; 168(4):3825-8. PMID: 23849968; PMCID: PMC4002741.
    47. Padler-Karavani V, Tremoulet A, Yu H, Chen X, Burns JC, Varki A. A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease. PLoS One. 2013; 8(3):e58443. PMID: 23520510; PMCID: PMC3592828.
    48. Shimizu C, Kim J, Stepanowsky P, Trinh C, Lau HD, Akers JC, Chen C, Kanegaye JT, Tremoulet A, Ohno-Machado L, Burns JC. Differential expression of miR-145 in children with Kawasaki disease. PLoS One. 2013; 8(3):e58159. PMID: 23483985; PMCID: PMC3590129.
    49. Kanegaye JT, Van Cott E, Tremoulet A, Salgado A, Shimizu C, Kruk P, Hauschildt J, Sun X, Jain S, Burns JC. Lymph-node-first presentation of Kawasaki disease compared with bacterial cervical adenitis and typical Kawasaki disease. J Pediatr. 2013 Jun; 162(6):1259-63, 1263.e1-2. PMID: 23305955; PMCID: PMC3637400.
    50. Jimenez-Fernandez SG, Tremoulet A. Infliximab treatment of pancreatitis complicating acute kawasaki disease. Pediatr Infect Dis J. 2012 Oct; 31(10):1087-9. PMID: 22653489; PMCID: PMC3444621.
    51. Bratincsak A, Reddy VD, Purohit PJ, Tremoulet A, Molkara DP, Frazer JR, Dyar D, Bush RA, Sim JY, Sang N, Burns JC, Melish MA. Coronary artery dilation in acute Kawasaki disease and acute illnesses associated with Fever. Pediatr Infect Dis J. 2012 Sep; 31(9):924-6. PMID: 22673140.
      View in: PubMed
    52. Ling XB, Kanegaye JT, Ji J, Peng S, Sato Y, Tremoulet A, Burns JC, Cohen HJ. Point-of-care differentiation of Kawasaki disease from other febrile illnesses. J Pediatr. 2013 Jan; 162(1):183-188.e3. PMID: 22819274; PMCID: PMC4186670.
    53. Broderick L, Tremoulet A, Burns JC, Hoffman HM. Prolonged urticaria and fever in a toddler. Allergy Asthma Proc. 2012 May-Jun; 33(3):297-301. PMID: 22584197; PMCID: PMC3490505.
    54. Tremoulet A, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, Tamamoto A, Erdem G, Dodd D, Burns JC. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2012 Sep; 161(3):506-512.e1. PMID: 22484354; PMCID: PMC3613150.
    55. Tremoulet A, Nikanjam M, Cressey TR, Chokephaibulkit K, McKinney R, Mirochnick M, Capparelli EV. Developmental pharmacokinetic changes of Lamivudine in infants and children. J Clin Pharmacol. 2012 Dec; 52(12):1824-32. PMID: 22180560; PMCID: PMC3369109.
    56. Tremoulet A, Jain S, Chandrasekar D, Sun X, Sato Y, Burns JC. Evolution of laboratory values in patients with Kawasaki disease. Pediatr Infect Dis J. 2011 Dec; 30(12):1022-6. PMID: 21817952; PMCID: PMC3222731.
    57. Tremoulet A, Devera G, Best BM, Jimenez-Fernandez S, Sun X, Jain S, Burns JC. Increased incidence and severity of Kawasaki disease among Filipino-Americans in San Diego county. Pediatr Infect Dis J. 2011 Oct; 30(10):909-11. PMID: 21552184.
      View in: PubMed
    58. Sato YZ, Molkara DP, Daniels LB, Tremoulet A, Shimizu C, Kanegaye JT, Best BM, Snider JV, Frazer JR, Maisel A, Burns JC. Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol. 2013 Mar 20; 164(1):58-63. PMID: 21777987; PMCID: PMC3253177.
    59. Broderick L, Tremoulet A, Burns JC, Bastian JF, Hoffman HM. Recurrent fever syndromes in patients after recovery from Kawasaki syndrome. Pediatrics. 2011 Feb; 127(2):e489-93. PMID: 21220401; PMCID: PMC3025426.
    60. Hong DK, Tremoulet A, Burns JC, Lewis DB. Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza a virus in intravenous immunoglobulin preparations. Pediatr Infect Dis J. 2011 Jan; 30(1):67-9. PMID: 20724956; PMCID: PMC3044211.
    61. Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet A, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011 Apr; 158(4):644-649.e1. PMID: 21129756.
      View in: PubMed
    62. Shimizu C, Jain S, Davila S, Hibberd ML, Lin KO, Molkara D, Frazer JR, Sun S, Baker AL, Newburger JW, Rowley AH, Shulman ST, Davila S, Burgner D, Breunis WB, Kuijpers TW, Wright VJ, Levin M, Eleftherohorinou H, Coin L, Popper SJ, Relman DA, Fury W, Lin C, Mellis S, Tremoulet A, Burns JC. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet. 2011 Feb; 4(1):16-25. PMID: 21127203; PMCID: PMC3073847.
    63. Fury W, Tremoulet A, Watson VE, Best BM, Shimizu C, Hamilton J, Kanegaye JT, Wei Y, Kao C, Mellis S, Lin C, Burns JC. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. Hum Immunol. 2010 Sep; 71(9):865-73. PMID: 20600450; PMCID: PMC2929310.
    64. Franco A, Shimizu C, Tremoulet A, Burns JC. Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease. Autoimmunity. 2010 Jun; 43(4):317-24. PMID: 20166878; PMCID: PMC2871072.
    65. Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Pancheri J, Tremoulet A, Watson VE, Best BM, Burns JC. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009 May; 123(5):e783-9. PMID: 19403470; PMCID: PMC2848476.
    66. Tremoulet A, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, Martin DD, Newburger JW, Burns JC. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008 Jul; 153(1):117-21. PMID: 18571548; PMCID: PMC2526555.
    67. Tremoulet A, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother. 2007 Dec; 51(12):4297-302. PMID: 17893155; PMCID: PMC2168008.
    68. Tremoulet A, Albani S. Novel therapies for rheumatoid arthritis. Expert Opin Investig Drugs. 2006 Nov; 15(11):1427-41. PMID: 17040201.
      View in: PubMed
    69. Tremoulet A, Albani S. Immunomics in clinical development: bridging the gap. Expert Rev Clin Immunol. 2005 May; 1(1):3-6. PMID: 20477648.
      View in: PubMed
    70. Tremoulet A, Avila-Aguero ML, París MM, Canas-Coto A, Ulloa-Gutierrez R, Faingezicht I. Albendazole therapy for Microsporidium diarrhea in immunocompetent Costa Rican children. Pediatr Infect Dis J. 2004 Oct; 23(10):915-8. PMID: 15602190.
      View in: PubMed